Article

Anti-tumor activity of camptothecin analog conjugate of a RSPO4-based peptibody targeting LGR4/5/6 in preclinical models of colorectal cancer

2024-10-11

Abstract excerpt

Antibody-drug conjugates (ADCs) have emerged as a major modality of targeted cancer therapy, yet no ADC has been approved specifically for colorectal cancer (CRC). LGR4/5/6 (leucine-rich repeat containing, G protein-coupled receptor 4, 5, 6) are three related receptors that are expressed at high levels together or alternately in nearly all cases of CRC. ADCs targeting LGR5 have been shown to have robust anti-tumor...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7680c889-414f-50b7-a644-16cd28ccf400
DOI: 10.1101/2024.10.08.616548

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Anti-tumor activity of camptothecin analog conjugate of a RSPO4-based peptibody targeting LGR4/5/6 in preclinical models of colorectal cancerDOI 10.1101/2024.10.08.616548Read

Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer modelsSemantic proximity Read

An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancerSemantic proximity Read

LGR5 targeting molecules as therapeutic agents for multiple cancer typesSemantic proximity Read

Novel immunotherapeutics against LGR5 to target multiple cancer typesSemantic proximity Read

CDK4/6 inhibitors enhance oxaliplatin efficacy in colorectal cancer with RB-dependent and tumor-selective activity in intestinal modelSemantic proximity Read

LGR5‐Positive Colon Cancer Stem Cells Interconvert with Drug‐Resistant LGR5‐Negative cells and are Capable of Tumor ReconstitutionSemantic proximity Read

Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatmentSemantic proximity Read

Experimental drugs for fallopian cancer: promising agents in the clinical trials and key stumbling blocks for researchers.Semantic proximity Read

Preclinical Drug Testing of the CDK 4/6 Inhibitor Palbociclib in Combination With a PI3K or MEK Inhibitor in Colorectal Cancer Cell LinesSemantic proximity Read

Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal CancerSemantic proximity Read

RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations.Semantic proximity Read

Logarithmic expansion of LGR5 + cells in human colorectal cancerSemantic proximity Read